KR20220164751A - Tyk2 억제제의 결정질 형태 - Google Patents

Tyk2 억제제의 결정질 형태 Download PDF

Info

Publication number
KR20220164751A
KR20220164751A KR1020227038120A KR20227038120A KR20220164751A KR 20220164751 A KR20220164751 A KR 20220164751A KR 1020227038120 A KR1020227038120 A KR 1020227038120A KR 20227038120 A KR20227038120 A KR 20227038120A KR 20220164751 A KR20220164751 A KR 20220164751A
Authority
KR
South Korea
Prior art keywords
compound
mixture
hours
crystalline form
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038120A
Other languages
English (en)
Korean (ko)
Inventor
존 찰스 리더
제이미 코너 마샬
존 미키티우크
줄리안 스콧 노튼
Original Assignee
사름 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사름 리미티드 filed Critical 사름 리미티드
Publication of KR20220164751A publication Critical patent/KR20220164751A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227038120A 2020-04-07 2021-04-06 Tyk2 억제제의 결정질 형태 Pending KR20220164751A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
GB2005114.0 2020-04-07
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor

Publications (1)

Publication Number Publication Date
KR20220164751A true KR20220164751A (ko) 2022-12-13

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038120A Pending KR20220164751A (ko) 2020-04-07 2021-04-06 Tyk2 억제제의 결정질 형태

Country Status (12)

Country Link
US (1) US12545652B2 (https=)
EP (1) EP4132649A1 (https=)
JP (1) JP7660135B2 (https=)
KR (1) KR20220164751A (https=)
CN (1) CN115515683B (https=)
AU (1) AU2021253128A1 (https=)
BR (1) BR112022016359A2 (https=)
CA (1) CA3167172A1 (https=)
GB (1) GB202005114D0 (https=)
IL (1) IL296989A (https=)
MX (1) MX2022011593A (https=)
WO (1) WO2021204762A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
WO2023183910A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Solid forms of tyk2 inhibitors and methods of use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
IL153246A0 (en) 2000-06-28 2003-07-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
DE60128731T2 (de) 2000-10-30 2008-02-07 Janssen Pharmaceutica N.V. Tripeptidylpeptidase-hemmer
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
JP5222561B2 (ja) 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008024980A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8420695B2 (en) 2008-07-09 2013-04-16 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN103987713A (zh) 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
EP3040336B1 (en) 2012-03-02 2020-04-08 Sareum Limited Compounds for use in treating tyk2 kinase mediated conditions
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
MX369974B (es) * 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
NO2721710T3 (https=) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB201816369D0 (en) * 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US20230159473A1 (en) 2023-05-25
BR112022016359A2 (pt) 2022-10-04
MX2022011593A (es) 2022-10-18
WO2021204762A1 (en) 2021-10-14
JP2023521631A (ja) 2023-05-25
US12545652B2 (en) 2026-02-10
CA3167172A1 (en) 2021-10-14
JP7660135B2 (ja) 2025-04-10
IL296989A (en) 2022-12-01
EP4132649A1 (en) 2023-02-15
CN115515683B (zh) 2024-10-25
AU2021253128A1 (en) 2022-08-25
GB202005114D0 (en) 2020-05-20
CN115515683A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
US11673870B2 (en) Pharmaceutical compounds
JP6239118B2 (ja) 医薬化合物
JP7660135B2 (ja) Ｔｙｋ２阻害剤の結晶形態
JP7383030B2 (ja) Ｔｙｋ２キナーゼ阻害剤
RU2805932C2 (ru) Фармацевтические соединения
HK40048146A (en) Tyk2 kinase inhibitors
HK40048146B (en) Tyk2 kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000